A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs AZD 9567 (Primary) ; Prednisolone
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 25 Aug 2017 Planned End Date changed from 4 Sep 2017 to 16 Oct 2017.
- 25 Aug 2017 Planned primary completion date changed from 4 Sep 2017 to 16 Oct 2017.
- 10 Jun 2017 Biomarkers information updated